Heavy alcohol use is taking an earlier toll, landing more young Americans onto transplant lists. The obesity epidemic makes ...

Published in JAMA Network Open, a new study found that less than half of Medicaid plans cover all four of the FDA-approved medications, which include acamprosate, disulfiram, and oral and injectable ...

Amid warnings of cancer's negative health effects, more people are turning to a trend known as "California sober." Health ...

For many Americans, St. Patrick’s Day is a moment to don green apparel and indulge in drinking a few – or more than a few – glasses of beer. But amid the merrymaking, we need to face a sobering ...

Current treatments, such as naltrexone or acamprosate, are underused due to their side effects or limited efficacy. Semaglutide could fill this therapeutic gap, offering a more accessible and ...

Acamprosate modulates glutamate neurotransmitter pathways through an unknown mechanism to reduce alcohol withdrawal hyperexcitability. Acamprosate has been shown to be beneficial in a subgroup of ...

which has lost almost all its value since Pharnext decided to abandon the development of its earlier lead candidate – PXT864 (baclofen and acamprosate) for Alzheimer’s disease – earlier this ...

o Pharmacologic: Naltrexone, acamprosate, disulfiram, gabapentin, topiramate, baclofen, ondansetron. Screening and SBIRT for PAU were considered relevant treatment services because they are often the ...

“Currently, only three medications are FDA-approved for AUD: disulfiram, acamprosate and naltrexone,” Soo Young Hwang, MD, a resident physician at University of Maryland Medical Center and ...